We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $186M
1-Year Est. Return 155.23%
This Fund
S&P 500
This Quarter Est. Return
+3.7%
1 Year Est. Return
+155.23%
3 Year Est. Return
+106.31%
5 Year Est. Return
+162.6%
10 Year Est. Return
+764.79%
AUM
$392M
AUM Growth
+$80.2M
Cap. Flow
+$84.9M
Cap. Flow %
21.66%
Top 10 Hldgs %
96.93%
Holding
17
New
4
Increased
–
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$56.2M
2
IMUX icon
Immunic
IMUX
+$18M
3
TRVI icon
Trevi Therapeutics
TRVI
+$10.9M
4
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$9.75M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$7.32M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.45M
3
PVLA
Palvella Therapeutics
PVLA
+$88.6K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
1
Gossamer Bio
GOSS
$83.2M
$154M 39.34%
6,953,416
– –
REPL icon
2
Replimune Group
REPL
$1.46B
$74.6M 19.02%
5,103,455
– –
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$58.9M 15.01%
+2,969,582
New +$56.2M
TBIO
4
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$30.8M 7.85%
2,437,603
– –
IMUX icon
5
Immunic
IMUX
$210M
$15.7M 4.01%
+137,149
New +$18M
OBSV
6
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.3M 2.88%
999,364
– –
PRTK
7
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.4M 2.65%
2,600,410
– –
TRVI icon
8
Trevi Therapeutics
TRVI
$2.39B
$9.48M 2.42%
+1,263,408
New +$10.9M
PRVL
9
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$8.83M 2.25%
+668,908
New +$9.75M
KYNB
10
Kyntra Bio
KYNB
$32.5M
$5.9M 1.51%
5,226
– –
PVLA
11
Palvella Therapeutics
PVLA
$2.16B
$3.55M 0.9%
9,431
-297
-3% -$88.6K
EPIX
12
DELISTED
ESSA Pharma
EPIX
$2.66M 0.68%
1,084,848
– –
JNCE
13
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.62M 0.67%
529,965
– –
CDTX
14
DELISTED
Cidara Therapeutics
CDTX
$2.54M 0.65%
75,440
– –
SNNA
15
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$660K 0.17%
758,610
– –
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
– –
-551,477
Closed -$7.32M
DRNA
17
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-167,157
Closed -$2.45M

Similar funds

LBC
Leigh Baldwin & Co Cazenovia, New York $186M AUM 40.09% 1-Year Est. Return
GWCM
Godshalk Welsh Capital Management Radnor, Pennsylvania $186M AUM 18.63% 1-Year Est. Return
FWM
Fingerlakes Wealth Management Ithaca, New York $186M AUM 30.5% 1-Year Est. Return
LOIP
Live Oak Investment Partners Austin, Texas $186M AUM 19.39% 1-Year Est. Return
TFA
Tranquilli Financial Advisor Clinton, New Jersey $186M AUM 18.12% 1-Year Est. Return
NCM
Northland Capital Management Virginia, Minnesota $186M AUM 16.43% 1-Year Est. Return
GPI
General Partner Inc Pittsburgh, Pennsylvania $186M AUM 25.15% 1-Year Est. Return
MWM
Melfa Wealth Management Westborough, Massachusetts $185M AUM 17.73% 1-Year Est. Return

Omega Fund Management's Q2 2019 Portfolio in Review

As of Q2 2019, Omega Fund Management held 17 positions worth $392M, up 26% from $312M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Omega Fund Management deployed $84.9M of net new capital in Q2 2019, opening 4 new positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 2,969,582 shares worth $58.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Palvella Therapeutics, an estimated $88.6K trimmed.

  • Omega Fund Management's largest Q2 2019 buy was Morphic Holding, Inc. Common Stock: 2,969,582 shares worth $58.9M.
  • Omega Fund Management's biggest Q2 2019 reduction was Palvella Therapeutics, cutting an estimated $88.6K.
  • Omega Fund Management fully exited Cymabay Therapeutics in Q2 2019, selling an estimated $7.32M.
  • Omega Fund Management's ten largest holdings make up 97% of its $392M portfolio in Q2 2019.
  • Omega Fund Management opened 4 new positions and closed 2 in Q2 2019.
  • Omega Fund Management's portfolio value rose 26% quarter-over-quarter to $392M.

Based on Omega Fund Management's 13F filing for Q2 2019, filed 13 Aug 2019.